Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Net Cash Flow (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Net Cash Flow for 4 consecutive years, with -$15.5 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 27.08% to -$15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.2 million through Dec 2025, up 117.63% year-over-year, with the annual reading at $10.2 million for FY2025, 117.63% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$15.5 million at Spruce Biosciences, down from $48.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $49.2 million in Q1 2023, with the low at -$25.6 million in Q3 2022.
  • Average Net Cash Flow over 4 years is $373625.0, with a median of -$9.4 million recorded in 2024.
  • The sharpest move saw Net Cash Flow crashed 829.95% in 2024, then surged 599.1% in 2025.
  • Over 4 years, Net Cash Flow stood at $2.9 million in 2022, then tumbled by 185.84% to -$2.5 million in 2023, then crashed by 765.58% to -$21.3 million in 2024, then grew by 27.08% to -$15.5 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$15.5 million, $48.1 million, and -$9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.